The drugs included in the warning are Pfizer’s Ibrance, Novartis’ Kisqali, and Eli Lilly’s Verzenio.
Though cases are rare, the FDA said the drugs could cause interstitial lung disease and pneumonitis.
The FDA warned patients taking the breast cancer drugs to watch for symptoms of pulmonary distress, including difficulty breathing and shortness of breath. Physicians should regularly monitor patients taking the drugs for symptoms of ILD and pneumonitis.
Patients who have developed ILD or pneumonitis should permanently stop taking the breast cancer drugs, the FDA said.
However, the FDA said the overall benefits of the breast cancer drugs are greater than the risks.
Read the full report here.
More articles on pharmacy:
Purdue Pharma files for bankruptcy
DEA proposes to cut opioid production in half
Pharmacist-led HIV prevention treatment program could boost patient satisfaction, study finds
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.